摘要:
The present invention relates to a new content substance found in leeches (Hirudo medicinalis), the derivatives of this abbreviated at the N-terminus and the C-terminus, and the desulfated derivatives therefrom as well as a process for the production of these compounds, and their use. These compounds possess thrombin-inhibiting properties and can be used to inhibit clotting in human and animals, for blood conservation, or as reagents for the analytical determination of thrombin.
摘要:
The present invention relates to desulfatohirudins, to the preparation thereof, to pharmaceutical compositions containing these compounds, and to the use thereof.The desulfatohirudins of this invention correspond to hirudin in biological activity and are therefore particularly useful for inhibiting blood clotting.
摘要:
The present invention relates to desulfatohirudins, to the preparation thereof, to pharmaceutical compositions containing these compounds, and to the use thereof. The desulfatohirudins of this invention correspond to hirudin in biological activity and are therefore particularly useful for inhibiting blood clotting.
摘要:
The present invention relates to desulfatohirudins, to the preparation thereof, to pharmaceutical compositions containing these compounds, and to the use thereof.The desulfatohirudins of this invention correspond to hirudin in biological activity and are therefore particularly useful for inhibiting blood clotting.
摘要:
The invention relates to novel, modified eglins B and C, to the preparation thereof, and to pharmaceutical compositions which contain these compounds. Compared with eglin B and C, the modification consists in a terminal shortening. The compounds of the invention can be prepared e.g. by limited enzymatic proteolysis of elgins or by peptide synthesis.
摘要:
There are described DNA sequences from the genome of mammals, in particular from the human genome, coding for proteins having the biological activity of HUSI-type I inhibitors. There are further described biotechnological methods of the preparation of proteins having the biological activity of HUSI-type I inhibitors as well as pharmaceutical compositions containing said proteins.